IP Library Granted Patent US 8,852,592
Granted Patent B2
US 8,852,592 · App. 14/004,400 · Granted Oct 7, 2014

Systems and methods for anti-PAX8 antibodies

Inventors: Weimin Qi (Martinez, CA); David Tacha (San Ramon, CA)
Assignee: Biocare Medical, LLC
C07K16/18C07K2317/34G01N33/574
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,852,592
App. No.
14/004,400
Granted
Oct 7, 2014
Kind
B2
Abstract

The present invention is related to the anti-PAX8 antibodies, kits, cocktails, and use of anti-PAX8 antibodies for detection of cancer.

Claims (61)

1. An antibody or fragment thereof produced by the hybridoma deposited with the American Type Culture Collection (ATCC) under ATCC Patent Deposit Designation No. PTA-11873, wherein said antibody or fragment thereof specifically binds to PAX8.

2. A hybridoma cell that is deposited at the American Type Culture Collection (ATCC) under ATCC Patent Deposit Designation No. PTA-11873.

3. A hybridoma cell according to claim 1 and further comprising an antibody or fragment thereof produced by said hybridoma cell.

4. A method for producing a monoclonal antibody according to claim 1 comprising the steps of:

culturing said hybridoma which produces a monoclonal antibody capable of specifically recognizing PAX8; and

allowing said hybridoma to produce the monoclonal antibody.

5. A composition comprising at least two antibodies or fragments thereof, wherein at least one of said at least two antibodies or fragments thereof comprises said antibody or said fragment thereof produced by said hybridoma according to claim 1 .

6. A composition according to claim 5 wherein said at least one other of said at least two antibodies or fragments thereof binds specifically to an antigen selected from a group consisting of GATA-3, p63, PSA, ER, Mammaglobin, GCDFP-15, NKX3.1, Napsin A, TTF-1, CK20, CDX2, ERG, and any combination thereof.

7. A composition according to claim 5 wherein at least two antibodies or fragments thereof each bind specifically to proteins selected from a group consisting of:

PAX8 and GATA-3;

PAX8 and p63;

PAX8 and PSA;

PAX8 and PSA and GATA-3;

PAX8 and ER and Mammoglobin and GCDFP-15;

PAX8 and ER;

PAX8 and Mammoglobin;

PAX8 and GCDFP-15;

PAX8 and NKX3.1;

PAX8 and Napsin A and TTF-1;

PAX8 and Napsin A;

PAX8 and TTF-1;

PAX8 and CD20 and CDX2;

PAX8 and CD20;

PAX8 and CDX2;

PAX8 and ERG and GATA-3; and

PAX8 and ERG.

8. An antibody according to claim 1 wherein said antibody or fragment thereof comprises a polypeptide of the amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO: 1 and SEQ ID NO: 2.

9. An antibody according to claim 1 wherein said antibody or fragment thereof specifically binds to at least one polypeptide with an amino acid sequence comprising residues of SEQ ID NO: 3.

10. An antibody according to claim 1 wherein said antibody or fragment thereof specifically binds to at least one polypeptide with an amino acid sequence that is at least 70% identical to residues of SEQ ID NO: 3.

11. An antibody according to claim 10 wherein said at least about 70% identical comprises a percentage selected from a group consisting of at least about 71%, at least about 72%, at least about 73%, at least about 74%, at least about 75%, at least about 76%, at least about 77%, at least about 78%, at least about 79%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, and at least about 99%.

12. An antibody according to claim 1 wherein said antibody comprises a monoclonal antibody.

13. An antibody according to claim 12 wherein said monoclonal antibody is selected from a group consisting of a mouse monoclonal antibody, a rabbit monoclonal antibody, a goat monoclonal antibody, a horse monoclonal antibody, a chicken monoclonal antibody, a humanized monoclonal antibody, a chimeric antibody, and any combination thereof.

14. An antibody according to claim 1 wherein said antibody comprises an isolated antibody.

15. An antibody according to claim 1 wherein said fragment thereof comprises an antigen binding fragment thereof.

16. An antibody according to claim 1 and further comprising a label attached to said antibody or fragment thereof.

17. A cancer diagnostic agent which comprises said antibody or fragment thereof according to claim 1 conjugated with a label.

18. An antibody according to claim 16 wherein said label is selected from a group consisting of a radioactive element, magnetic particles, radioisotope, fluorescent dye, enzyme, toxin, signal, stain, and any combination thereof.

19. An antibody according to claim 17 wherein said label is selected from a group consisting of a radioactive element, magnetic particles, radioisotope, fluorescent dye, enzyme, toxin, signal, stain, and any combination thereof.

20. A diagnostic test kit comprising:

an antibody or fragment thereof according to claim 1 ; and

an antibody detection element of said antibody or said fragment thereof when bound to an antigen.

21. A method for detecting PAX8 in a biological sample using the kit of claim 20 comprising the steps of:

contacting a biological sample with said antibody or fragment thereof; and

detecting binding of said antibody with an antigen in said biological sample using said antibody detection element.

22. A method according to claim 21 wherein said biological sample is selected from a group consisting of a normal tissue, neoplastic tissue, kidney tissue, ovarian tissue, thyroid tissue, endometrial tissue, renal tissue, tonsil tissue, pancreas tissue, colon tissue, lymph node tissue, neoplastic pancreatic tissue, stomach tissue, bladder tissue, prostate tissue, lung tissue and breast tissue.

23. An antibody according to claim 1 wherein said antibody or fragment thereof does not specifically bind to B-cells.

24. An antibody according to claim 1 wherein said antibody or fragment thereof does not specifically bind to cells selected from a group consisting of neuroendocrine cells, pancreatic cells, and any combination thereof.

25. A method for detecting a protein to which an antibody or fragment thereof of claim 1 binds to a biological sample, comprising the steps of contacting a biological sample with the antibody or fragment thereof; and detecting the presence of the antibody or fragment thereof bound to the protein in the biological sample.

26. A method according to claim 25 wherein said biological sample is selected from a group consisting of a normal tissue, neoplastic tissue, kidney tissue, ovarian tissue, thyroid tissue, endometrial tissue, renal tissue, tonsil tissue, pancreas tissue, colon tissue, lymph node tissue, neoplastic pancreatic tissue, stomach tissue, bladder tissue, prostate tissue, lung tissue and breast tissue.

27. A method according to claim 25 wherein said detecting said presence of the antibody or fragment thereof bound to the protein is performed on an automated staining device.

28. A method according to claim 25 wherein said detecting said presence of the antibody or fragment thereof bound to the protein is made manually.

29. A method according to claim 25 wherein said detecting said presence of the antibody or fragment thereof bound to the protein is made automatically.

30. A method according to claim 25 wherein said detecting said presence of the antibody or fragment thereof bound to the protein is made by image analysis.

31. A method according to claim 25 wherein said detecting comprises a method selected from a group consisting of immunohistochemistry (IHC), IHC of FFPE, IHC of frozen-tissue sections, and ELISA.

32. An immunoassay method for detecting PAX8 protein in an animal or human comprising the steps of:

obtaining tissue from an animal or human to be tested;

fixing or freezing said tissue;

treating said fixed or frozen tissue to unmask epitopes to PAX8;

contacting said treated tissue with an antibody or fragment thereof according to claim 1 , in an amount and under conditions such that said antibody or fragment thereof binds to a PAX8 protein if said protein is present in said tissue; and

detecting the presences of said bound antibodies.

33. An immunoassay method for detecting PAX8 protein according to claim 32 and further comprising detecting said PAX8 protein in said animal or human with a method selected from a group consisting of immunohistochemistry (IHC), IHC of FFPE, IHC of frozen-tissue sections, and ELISA.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Jun 25, 2026
From: VARAGON CAPITAL PARTNERS AGENT, LLC, AS ADMINISTRATIVE AGENT
To: BIOCARE MEDICAL LLC
Reel/Frame 075082/0723 →
RELEASE OF SECURITY INTEREST Recorded Dec 9, 2021
From: VARAGON CAPITAL PARTNERS AGENT, LLC, AS ADMINISTRATIVE AGENT
To: BIOCARE MEDICAL LLC
Reel/Frame 058351/0058 →
SECURITY INTEREST Recorded Dec 9, 2021
From: BIOCARE MEDICAL LLC
To: VARAGON CAPITAL PARTNERS AGENT, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 058344/0799 →
SECURITY INTEREST Recorded Aug 25, 2017
From: BIOCARE MEDICAL LLC
To: VARAGON CAPITAL PARTNERS AGENT, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 043401/0661 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT BUSINESS ENTITY TYPE ON THE PREVIOUSLY RECORDED DOCUMENT PREVIOUSLY RECORDED AT REEL: 031182 FRAME: 0135. ASSIGNOR(S) HEREBY CONFIRMS THE NUNC PRO TUNC ASSIGNMENT. Recorded Dec 5, 2014
From: QI, WEIMIN; TACHA, DAVID
To: BIOCARE MEDICAL, LLC
Reel/Frame 034535/0698 →
NUNC PRO TUNC ASSIGNMENT Recorded Sep 20, 2013
From: QI, WEIMIN; TACHA, DAVID
To: BIOCARE MEDICAL, LLC
Reel/Frame 031252/0562 →
NUNC PRO TUNC ASSIGNMENT Recorded Sep 11, 2013
From: QI, WEIMIN; TACHA, DAVID
To: BIOCARE MEDICAL, LLC
Reel/Frame 031182/0135 →
Continuity (3)
Provisional Application 61484579 · May 10, 2011
Provisional Application 61588035 · Jan 18, 2012
Related Publication 20140004542A1 · Jan 2, 2014